Mukherjee Labs Preclinical Imaging

Design and Development of Novel Imaging Methods for Early Diagnosis of Diseases

You are here: Home / Publications / Alzheimer’s Disease

Alzheimer’s Disease

  • Ghazaryan, N., Patel, K.K., Samra, G.K., Mukherjee J. Nicotinic a4b2* receptors in anterior cingulate of postmortem human Alzheimer’s disease and Parkinson’s disease brain. Journal of Nuclear Medicine, Vol. 60, Supplement 1, 1305, 2019. Presented at the 66th Annual Meeting of Society of Nuclear Medicine and Molecular Imaging, Anaheim, California, June 22-25, 2019.

 

  • Samra, G.K., Dang K., Ho, H., Baranwal, A., Mukherjee J. Dual targeting agents for Aβ plaque/P-glycoprotein and Aβ plaque/nicotinic acetylcholine α4β2* receptors – Potential approaches to facilitate Aβ Plaque removal in Alzheimer’s disease brain Medicinal Chemistry Research, 27(6): 1634-1646, 2018.(DOI: 10.1007/s00044-018-2178-9).

 

  • Coleman, R.A., Liang, C., Patel, R., Ali, S., Mukherjee, J.: Brain and brown adipose tissue metabolism in Tg 2576 transgenic mice models of Alzheimer’s disease assessed using 18F-FDG PET.  Molecular Imaging, 16: 1-9, 2017.

 

  • Ho, H.M., Baranwal A, Mukherjee J. Evaluation of fluorinated TAZA analogs as potential ligands for Ab plaques. J. Nucl. Med., 57 (6)suppl: 1031, 2016 (Presented at the 63rd Annual Meeting of Societyof Nuclear Medicine, San Diego, CA, June 11-15, 2016).

 

  • Pan, M.L., Mukherjee, M.T., Patel, H.H., Patel, B., Constantinescu, C.C., Mirbolooki, M.R., Liang, C., Mukherjee, J.: Evaluation of [11C]TAZA for amyloid Aß plaque imaging in postmortem Alzheimer’s disease brain region and whole body distribution in rodent PET/CT. Synapse, 70: 163-176, 2016 (published online January 2016; Editor’s Choice Paper).

 

  • Shah N, Mukherjee J. Glutamate-induced hyperactivity of NMDA ion channel in postmortem Alzheimer’s disease brains. J. Nucl. Med., 56 (suppl): 411, 2015 (Presented at the 62nd Annual Meeting of Society of Nuclear Medicine, Baltimore, MD, June 6-10, 2015).

 

  • Venugopal A, Mukherjee J. Serotonin and dopamine receptor changes in post-mortem Alzheimer’s disease brain. Abstract # P-107 Presented at the 10th International Symposium on Functional Neuroreceptor Mapping of the Living Brain, Egmond aan Zee, The Netherlands, May 21-24, 2014).

 

  • Kuruvilla S, Mukherjee J. Acetylcholine breakdown is greater in postmortem Alzheimer’s disease frontal cortex. Abstract # P-108 Presented at the 10th International Symposium on Functional Neuroreceptor Mapping of the Living Brain, Egmond aan Zee, The Netherlands, May 21-24, 2014).

 

  • Kuruvilla S, Mukherjee J. Suppression of acetylcholine breakdown by butyrylcholinesterase inhibitor in postmortem Alzheimer’s disease brain. J. Nucl. Med., 55 (suppl): 416, 2014 (Presented at the 61th Annual Meeting of Society of Nuclear Medicine, St. Louis, MO, June 7-11, 2014).

 

  • Kuruvilla S, Bajwa A, Patel H, Pan ML, Mukherjee J. Reduction of nicotinic a4b2 receptors in postmortem human Alzheimer’s disease brain. J. Nucl. Med., 54 (suppl):472, 2013 (Presented at the 60th Annual Meeting of Society of Nuclear Medicine, Vancouver, Canada, June 8-12, 2013).

 

  • The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget’s disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. Nalbandian A, Donkervoort S, Dec E, Badadani M, Katheria V, Rana P, Nguyen C, Mukherjee J, Caiozzo V, Martin B, Watts GD, Vesa J, Smith C, Kimonis VE. J Mol Neurosci. 2011 Nov;45(3):522-31. doi: 10.1007/s12031-011-9627-y. Epub 2011 Sep 3. Review. PMID: 21892620